Sciele Pharma And Plethora Solutions Announce Final Analysis Of PSD502 For Premature Ejaculation; All Primary And Secondary Endpoints Met In Phase III
Dec 11th 2008Drug InformationErectile Dysfunction / Premature Ejaculation
Sciele Pharma, Inc., a Shionogi Company, and Plethora Solutions Holdings PLC (”Plethora” - AIM:PLE), the specialist developer of products for the treatment and management of urological disorders, today announced the final analysis of its European Phase III double-blind placebo-controlled study of PSD502 for the treatment of premature ejaculation (’PE’).
More: continued here